Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.38 |
| ▸ | FNTA | P49354 | 3/20 | 0.37 |
| ▸ | FNTB | P49356 | 3/20 | 0.37 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL8521540 | 0.83 | GABRR1 (0.46) | GRIK1GRIK2GABRR1FNTAFNTB | |
| Lactic Acid SCHEMBL4379980 | 0.78 | TP53 (0.58) | TP53GRIK1GRIK2GABRR1SLC7A5 | |
| Lactic Acid SCHEMBL6153584 | 0.77 | TP53 (0.50) | TP53GRIK1GRIK2ALDH1A1FNTA | |
| SCHEMBL77915 | 0.77 | — | — | |
| Fumaric Acid SCHEMBL10917256 | 0.76 | TSHR (0.50) | TP53ALDH1A1GABRR1ABATKDM4E | |
| Fumaric Acid SCHEMBL10917265 | 0.76 | TSHR (0.50) | TP53ALDH1A1GABRR1ABATKDM4E | |
| Lactic Acid SCHEMBL1025752 | 0.76 | TP53 (0.55) | TP53GRIK1GRIK2ALDH1A1GABRR1 | |
| Lactic Acid SCHEMBL28848648 | 0.75 | TP53 (0.61) | TP53GABRR1SLC7A5 | |
| Lactic Acid SCHEMBL7195657 | 0.75 | — | — | |
| Lactic Acid SCHEMBL27979213 | 0.75 | TP53 (0.69) | TP53GABRR1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 472 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752137-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | European Molecular Biology Laboratory (DE) | 2020-12-23 | — | — | EP | claimed |
| US-20200368218-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2020-11-26 | — | — | US | claimed |
| WO-2019158559-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2019-08-22 | — | — | WO | claimed |
| EP-3524237-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | European Molecular Biology Laboratory (DE) | 2019-08-14 | — | — | EP | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2011-11-03 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| US-7829116-B2 | Silylated polyurethanes; pressure sensitive adhesives; transdermal drug delivery | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2010-11-09 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| EP-2104695-A2 | ADHESIVE-FORMING COMPOSITION AND BLEND OF ADHESIVES OBTAINED THEREFROM | Momentive Performance Materials Inc. (US) | 2009-09-30 | — | — | EP | claimed |
| US-20070249581-A1 | Abnormal Cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. | 2007-10-25 | — | — | US | claimed |
| US-20070249731-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. | 2007-10-25 | — | — | US | claimed |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2007-10-25 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| US-20050282902-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. | 2005-12-22 | — | — | US | claimed |
| US-5589395-A | BRINGING BIOLOGICAL FLUID SAMPLE INTO CONTACT WITH AGENT CONTAINING ANTICOAGULANT, CHELATE-FORMING AGENT AND AGGREGATION-INHIBITING SUBSTANCE FROM LIST SPECIFIED | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1996-12-31 | — | — | US | claimed |
| EP-0433927-B1 | Substance to improve the recovery of annexins | BEHRINGWERKE AG (DE) | 1995-09-20 | — | — | EP | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249581-A1 | Abnormal Cannabidiols as agents for lowering intraocular pressure | CNR2, CNR1, PTGIR | TP53 4820/4885GRIK1 1701/4885GRIK2 1817/4885 |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | TP53 4830/4885GRIK1 1704/4885GRIK2 1764/4885 |
| US-20070249731-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | CNR2, CNR1, PTGIR | TP53 4820/4885GRIK1 1701/4885GRIK2 1817/4885 |
| US-20050282902-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | CNR2, CNR1, FAAH2 | TP53 4867/4885GRIK1 1119/4885GRIK2 632/4885 |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | TP53 4830/4885GRIK1 1704/4885GRIK2 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.